Khiron is going to invest in an education platform for Latin America

The most studied cannabinoids are cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC), which have specific therapeutic properties and are considered as a complementary therapy for some chronic-degenerative and oncological diseases. Khiron, a Colombian cannabis company, announces about investing in education including clinical studies and applied scientific evidence.

A Latin America focused distance learning platform on medical cannabis, exclusive to health professionals, will be launched this year. The business will begin in Colombia. Then will be also settled in other countries with advanced regulations, such as Uruguay. In Brazil, there is still no date for the platform to begin operating.

Visit our Hemp.im mobile application to check the latest news in marijuana news and other trending topics like hemp and marijuana. Hemp.im will bring you the best business news experience on your Android and iOS devices.

Khiron to invest in education in Brazil

The announcement was made by Khiron, a cannabis company, on Friday, February 14th, during a meeting with Brazilian federal deputies Luciano Ducci (PSB-PR), Paulo Costa (PTB-PA) and Paulo Teixeira (PT-SP), in Bogotá, in the office located in the wooded neighborhood of El Chicó – the equivalent of Jardins, in São Paulo, Brazil. “The market needs well-prepared doctors,” said CEO Álvaros Torres.

The deputies are part of the Cannabis Study Committee set up in the Chamber of Deputies to study and  elaborate a regulation for the national market. The trip was a field study to broaden the knowledge of lawmakers, who exchanged experiences and discussed obstacles and advances in the markets. Their challenge is to deliver a proposal for regulation in April.

Colombian operating company

Khiron is operating in Colombia. The company was founded six years ago – and since everything in the cannabis business is new, it can be considered a veteran of the market. In 2018, the company went public on the Toronto Stock Exchange in Canada.

It is currently investing in research, cultivation, medical cannabis production, cosmetics manufacturing and most recently is opening another business door through distance education.

How the platform works

The course will have 13 modules, which will include basic cannabis information and, in the end, clinical studies and applied scientific evidence. “Only health professionals will be able to participate,” said Torres.

In the end, the students will receive a certificate: “Investment in education is one of the company’s most important goals. The doctor needs to be prepared in order to prescribe medical cannabis.” In Brazil, there are companies that are already operating in this sector, such as OnixCann/Cantera. However, the courses are still in attendance and have a shorter format.

“Given the advances in research and openness in the jurisdiction of various Latin American nations regarding the use of cannabinoids, it is essential to strengthening medical education for their proper use in various conditions,” said the specialist, Maria Fernanda Arboleda Castro.

“There are several possibilities in the use of medical cannabis in various health practices, however, continuing education should be promoted to strengthen knowledge and ensure responsible, ethical and safe prescription by the medical community,” said the director of Khiron Life Sciences Corp, a medical cannabis company.

Khiron has a partner in Brazil

In Colombia, Khiron’s e-learning debut comes in the third quarter of the year. In Brazil, the company already has a partner in the business. Who is it? Torres keeps it a secret. “Can’t tell yet.” Okay, but when does it debut here? “As soon as the country’s new regulation is approved.” No one can guarantee how long it will take for the bill to become law. Torres is excited. Believes it’s still in 2020. Let’s wait.

__

(Featured image by Tim Mossholder via Unsplash)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Hemp.im, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in SECHAT, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Hemp.im assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Hemp.im is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.